BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Price & Overview

TSX:BCTCA1079303071

Current stock price

5.17 CAD
-0.21 (-3.9%)
Last:

The current stock price of BCT.CA is 5.17 CAD. Today BCT.CA is down by -3.9%. In the past month the price decreased by -0.77%. In the past year, price decreased by -99.09%.

BCT.CA Key Statistics

52-Week Range4.95 - 1350
Current BCT.CA stock price positioned within its 52-week range.
1-Month Range4.95 - 6.31
Current BCT.CA stock price positioned within its 1-month range.
Market Cap
37.483M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-177.80
Dividend Yield
N/A

BCT.CA Stock Performance

Today
-3.9%
1 Week
-9.30%
1 Month
-0.77%
3 Months
-54.00%
Longer-term
6 Months -66.49%
1 Year -99.09%
2 Years -99.91%
3 Years -99.97%
5 Years -99.93%
10 Years -98.77%

BCT.CA Stock Chart

BRIACELL THERAPEUTICS CORP / BCT Daily stock chart

BCT.CA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BCT.CA. When comparing the yearly performance of all stocks, BCT.CA is a bad performer in the overall market: 98.73% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BCT.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to BCT.CA. BCT.CA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BCT.CA Earnings

Next Earnings DateJun 15, 2026
Last Earnings DateMar 10, 2026
PeriodQ2 / 2026
EPS Reported-$2.58
Revenue Reported
EPS Surprise 47.22%
Revenue Surprise %

BCT.CA Forecast & Estimates


Analysts
Analysts80
Price TargetN/A
EPS Next Y90.98%
Revenue Next YearN/A

BCT.CA Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

BCT.CA Financial Highlights

Over the last trailing twelve months BCT.CA reported a non-GAAP Earnings per Share(EPS) of -177.8. The EPS decreased by -184.87% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-28.71M
Industry RankSector Rank
PM (TTM) N/A
ROA -219.56%
ROE -287.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%88.93%
Sales Q2Q%N/A
EPS 1Y (TTM)-184.87%
Revenue 1Y (TTM)N/A

BCT.CA Ownership

Ownership
Inst Owners1.05%
Shares7.25M
Float7.23M
Ins Owners0.05%
Short Float %N/A
Short RatioN/A

About BCT.CA

Company Profile

BCT logo image BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.

Company Info

IPO: 2006-10-12

BRIACELL THERAPEUTICS CORP

Suite 300 - Bellevue Centre, 235 -15th Street

West Vancouver BRITISH COLUMBIA V7T 2X1 CA

CEO: William Williams

Employees: 20

BCT Company Website

BCT Investor Relations

Phone: 16049211810

BRIACELL THERAPEUTICS CORP / BCT.CA FAQ

What does BCT do?

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. The company is headquartered in West Vancouver, British Columbia and currently employs 20 full-time employees. The company went IPO on 2006-10-12. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The firm is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. The company is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.


Can you provide the latest stock price for BRIACELL THERAPEUTICS CORP?

The current stock price of BCT.CA is 5.17 CAD. The price decreased by -3.9% in the last trading session.


Does BCT stock pay dividends?

BCT.CA does not pay a dividend.


How is the ChartMill rating for BRIACELL THERAPEUTICS CORP?

BCT.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the sector and industry classification for BRIACELL THERAPEUTICS CORP?

BRIACELL THERAPEUTICS CORP (BCT.CA) operates in the Health Care sector and the Biotechnology industry.


Can you provide the market cap for BRIACELL THERAPEUTICS CORP?

BRIACELL THERAPEUTICS CORP (BCT.CA) has a market capitalization of 37.48M CAD. This makes BCT.CA a Nano Cap stock.


What is the ownership structure of BRIACELL THERAPEUTICS CORP (BCT.CA)?

You can find the ownership structure of BRIACELL THERAPEUTICS CORP (BCT.CA) on the Ownership tab.